The EU pharmaceutical package aims to accelerate life sciences industries growth and promote sustainable healthcare systems for European patients. Patient access, market access, availability disparities, supply shortages, and supply chain and innovation challenges drive review and reform of the EU pharmaceutical legislation—the foundation of pharmaceutical industry manufacturing of safe, effective, high quality medicinal products in Malta and European countries.
In Malta’s healthcare sector, the pricing and reimbursement strategies for medicinal products and medical devices reflect a distinct dual-market system. The public sector, driven by principles of social solidarity, offers patients access to essential medications free of charge, selected from a government-regulated formulary.
i Classification The Medicines Authority’s Borderline Classification Committee distinguishes between medicinal and non-medicinal products. Assessments are made on a case-by-case… read more →